share_log

Theravance Biopharma Analyst Ratings

Theravance Biopharmaアナリストの評価

Benzinga ·  2023/08/08 06:13
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/08/2023 103.46% HC Wainwright & Co. → $20 Reiterates Buy → Buy
05/09/2023 103.46% HC Wainwright & Co. $19 → $20 Maintains Buy
02/28/2023 93.29% HC Wainwright & Co. → $19 Reiterates → Buy
11/17/2022 42.42% SVB Leerink $12 → $14 Maintains Outperform
11/08/2022 93.29% HC Wainwright & Co. $12 → $19 Maintains Buy
07/25/2022 1.73% Morgan Stanley $11 → $10 Maintains Underweight
05/23/2022 22.08% SVB Leerink → $12 Initiates Coverage On → Outperform
03/02/2022 11.9% Morgan Stanley $10 → $11 Maintains Underweight
02/24/2022 22.08% HC Wainwright & Co. $8 → $12 Maintains Buy
11/05/2021 22.08% JP Morgan $7 → $12 Upgrades Underweight → Neutral
09/16/2021 1.73% Morgan Stanley $14 → $10 Maintains Underweight
09/16/2021 -18.62% HC Wainwright & Co. $21 → $8 Maintains Buy
09/16/2021 1.73% SVB Leerink $29 → $10 Maintains Outperform
08/25/2021 42.42% Morgan Stanley $27 → $14 Downgrades Overweight → Underweight
08/24/2021 42.42% Cowen & Co. $42 → $14 Downgrades Outperform → Market Perform
08/24/2021 195.02% SVB Leerink $37 → $29 Maintains Outperform
08/24/2021 83.11% Needham $32 → $18 Maintains Buy
08/24/2021 113.63% HC Wainwright & Co. $32 → $21 Maintains Buy
08/04/2021 276.4% SVB Leerink $36 → $37 Maintains Outperform
07/16/2021 174.67% Morgan Stanley $28 → $27 Maintains Overweight
06/28/2021 266.23% SVB Leerink $39 → $36 Maintains Outperform
05/13/2021 184.84% Morgan Stanley $30 → $28 Maintains Overweight
05/05/2021 225.53% Needham $40 → $32 Maintains Buy
05/05/2021 296.74% SVB Leerink $40 → $39 Maintains Outperform
04/01/2021 306.92% SVB Leerink $41 → $40 Maintains Outperform
03/01/2021 205.19% Morgan Stanley $31 → $30 Maintains Overweight
02/24/2021 317.09% SVB Leerink $35 → $41 Maintains Outperform
12/16/2020 215.36% Morgan Stanley $32 → $31 Maintains Overweight
11/24/2020 205.19% Evercore ISI Group → $30 Reinstates → Outperform
11/06/2020 256.05% SVB Leerink $40 → $35 Maintains Outperform
10/14/2020 Morgan Stanley Upgrades Equal-Weight → Overweight
08/10/2020 205.19% Piper Sandler $35 → $30 Maintains Overweight
08/10/2020 195.02% Morgan Stanley $30 → $29 Maintains Equal-Weight
07/07/2020 195.02% JP Morgan → $29 Initiates Coverage On → Overweight
06/15/2020 205.19% Morgan Stanley → $30 Initiates Coverage On → Equal-Weight
05/13/2020 327.26% Cowen & Co. → $42 Initiates Coverage On → Outperform
02/25/2020 225.53% HC Wainwright & Co. $30 → $32 Maintains Buy
02/25/2020 256.05% Piper Sandler $40 → $35 Maintains Overweight
11/06/2019 83.11% Baird $22 → $18 Upgrades Underperform → Neutral
10/29/2019 154.32% HC Wainwright & Co. → $25 Initiates Coverage On → Buy

What is the target price for Theravance Biopharma (TBPH)?

The latest price target for Theravance Biopharma (NASDAQ: TBPH) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $20.00 expecting TBPH to rise to within 12 months (a possible 103.46% upside). 5 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Theravance Biopharma (TBPH)?

The latest analyst rating for Theravance Biopharma (NASDAQ: TBPH) was provided by HC Wainwright & Co., and Theravance Biopharma reiterated their buy rating.

When is the next analyst rating going to be posted or updated for Theravance Biopharma (TBPH)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theravance Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theravance Biopharma was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.

Is the Analyst Rating Theravance Biopharma (TBPH) correct?

While ratings are subjective and will change, the latest Theravance Biopharma (TBPH) rating was a reiterated with a price target of $0.00 to $20.00. The current price Theravance Biopharma (TBPH) is trading at is $9.83, which is within the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする